XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

April 16-20, 2016 | New Orleans | Annual AACR meeting

Xentech is pleased to announce its participation to the prestigious American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans in April 16-20, 2016.   Visit us at booth #1053   And   Meet our scientists at the poster sessions. Poster # 2923 : Functional evaluation of interferon/STAT1 pathway activation in response to […]


Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....


Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...